SuperworthPrelude Therapeutics shares outstanding PRLD
Diluted shares outstanding, averaged over each quarter, from 2019.
- Latest quarter, to Jun 30, 2026
- 98.4M
- On a year earlier
- +29.5%
- more shares
Prelude Therapeutics had 98.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 29.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 79.7M | +5% |
| FY2024 | 75.9M | +9% |
| FY2023 | 69.5M | +46% |
| FY2022 | 47.7M | +2% |
| FY2021 | 46.7M | +2485% |
| FY2019 | 1.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 98.4M | +29% | |
| Q1 FY26 | 82.5M | +9% | |
| Q4 FY25 | 79.7M | +5% | |
| Q3 FY25 | 76.1M | +0% | |
| Q2 FY25 | 76M | +0% | |
| Q1 FY25 | 76M | +0% | |
| Q4 FY24 | 75.9M | +9% | |
| Q3 FY24 | 75.9M | +12% | |
| Q2 FY24 | 75.8M | +35% | |
| Q1 FY24 | 75.7M | +59% | |
| Q4 FY23 | 69.5M | +46% | |
| Q3 FY23 | 67.6M | +43% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Prelude Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.